| Dr Lynn Daria Jablonowski, OD | |
|
105 Freeport Rd, Suite 2, Aspinwall, PA 15215-2943 | |
| (412) 781-1120 | |
| (412) 781-1130 |
| Full Name | Dr Lynn Daria Jablonowski |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 36 Years |
| Location | 105 Freeport Rd, Aspinwall, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871715276 | NPI | - | NPPES |
| 1724972 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OEG001873 (Pennsylvania) | Primary |
| Provider Name | Aspinwall Eye Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093263980 PECOS PAC ID: 8426337718 Enrollment ID: O20161109000174 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.
Obese intensive care patients do not have a higher ICU death rate than non-obese ICU patients, but they remain in the ICU significantly longer and are intubated significantly longer than non-obese patients, a new study has found.
It was already known that people affected by Parkinson's disease, when subjected to deep brain stimulation, gained weight, but it was less clear why that was so. Thanks to new research by the International School for Advanced Studies - SISSA in Trieste, it has been realized that the weight gain after implant has a multifactorial origin.
Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.
Surfaces coated with a quaternary ammonium polymer have remarkable antiviral properties. They may even be capable of reducing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in areas with high risk for contamination, such as indoor environments or public places. University of Arizona researchers explain the antiviral potential of these in a new study published on the preprint server medRxiv.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lynn Daria Jablonowski, OD 317 Kittanning Pike, Pittsburgh, PA 15215-1117 Ph: (412) 781-8859 | Dr Lynn Daria Jablonowski, OD 105 Freeport Rd, Suite 2, Aspinwall, PA 15215-2943 Ph: (412) 781-1120 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.
Obese intensive care patients do not have a higher ICU death rate than non-obese ICU patients, but they remain in the ICU significantly longer and are intubated significantly longer than non-obese patients, a new study has found.
It was already known that people affected by Parkinson's disease, when subjected to deep brain stimulation, gained weight, but it was less clear why that was so. Thanks to new research by the International School for Advanced Studies - SISSA in Trieste, it has been realized that the weight gain after implant has a multifactorial origin.
Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.
Surfaces coated with a quaternary ammonium polymer have remarkable antiviral properties. They may even be capable of reducing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in areas with high risk for contamination, such as indoor environments or public places. University of Arizona researchers explain the antiviral potential of these in a new study published on the preprint server medRxiv.
› Verified 6 days ago
Kieffer Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 405 Loop St, Aspinwall, PA 15215 Phone: 412-781-1535 Fax: 412-781-1599 |